Clene Inc. (NASDAQ:CLNN – Free Report) – Stock analysts at HC Wainwright raised their FY2026 EPS estimates for shares of Clene in a research report issued on Wednesday, November 4th. HC Wainwright analyst J. Pantginis now expects that the company will post earnings per share of ($1.07) for the year, up from their previous estimate of ($1.69). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Clene’s current full-year earnings is ($1.70) per share. HC Wainwright also issued estimates for Clene’s Q4 2026 earnings at ($0.55) EPS, FY2027 earnings at ($0.92) EPS and FY2028 earnings at ($0.60) EPS.
Separately, Weiss Ratings cut shares of Clene from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, October 27th. Six equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Clene presently has an average rating of “Moderate Buy” and a consensus price target of $34.00.
Clene Stock Performance
CLNN opened at $3.97 on Friday. Clene has a fifty-two week low of $3.02 and a fifty-two week high of $11.23. The firm has a 50-day moving average of $3.90 and a 200 day moving average of $5.14. The firm has a market cap of $51.59 million, a P/E ratio of -1.53 and a beta of 1.04.
Clene (NASDAQ:CLNN – Get Free Report) last announced its earnings results on Wednesday, November 4th. The company reported $0.05 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.50. The business had revenue of $0.06 million during the quarter, compared to analysts’ expectations of $0.07 million.
Clene Company Profile
Clene Inc is a clinical-stage biopharmaceutical company developing nanotherapeutic treatments for neurodegenerative diseases. The company’s lead product candidate, CNM-Au8, is an investigational oral suspension containing catalytically active gold nanocrystals designed to support cellular energy production and reduce oxidative stress, with the goal of protecting and improving the function of nerve cells.
Clene has studied CNM-Au8 in conditions including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), and has also investigated its potential applications in other neurodegenerative disorders.
Featured Stories
- Five stocks we like better than Clene
- Google’s Credit Backstop May Be TeraWulf’s Biggest Advantage
- Could the Midterms Revive Medicare for All? 3 Healthcare Stocks to Watch
- Qualcomm Beat Earnings, But Its Fastest-Growing Businesses Have a Catch
- Oil, Uranium, or Renewables? 3 Energy Plays for a Changing Market
Receive News & Ratings for Clene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clene and related companies with MarketBeat.com's FREE daily email newsletter.
